Spots Global Cancer Trial Database for PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Official Title: Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum Doublet Chemotherapy and Other Immunooncology Agents in PD-L1 Unselected, Metastatic NSCLS Patients (ElevatION:NSCLC-101 Trial)
Study ID: NCT03064854
Conditions
Study Description
Brief Summary: The primary purpose of this study is to establish the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of PDR001 when administered in combination with platinum-doublet chemotherapy and other immunooncology agent(s) in treatment naive patients with PD-L1 unselected, advanced NSCLC, and to estimate the preliminary anti-tumor activity in this patient population.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Highlands Oncology Group, Fayetteville, Arkansas, United States
UCLA Santa Monica Hematology / Oncology SC-2, Santa Monica, California, United States
Stanford Cancer Center SC, Stanford, California, United States
Henry Ford Health System SC, Detroit, Michigan, United States
Washington University School of Medicine SC, Saint Louis, Missouri, United States
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Roeselare, , Belgium
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Praha 4, , Czechia
Novartis Investigative Site, Lyon Cedex, , France
Novartis Investigative Site, Marseille Cedex 05, , France
Novartis Investigative Site, Gottingen, , Germany
Novartis Investigative Site, Koeln, , Germany
Novartis Investigative Site, Pokfulam, , Hong Kong
Novartis Investigative Site, Meldola, FC, Italy
Novartis Investigative Site, Rozzano, MI, Italy
Novartis Investigative Site, Aviano, PN, Italy
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Amsterdam, , Netherlands
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
